Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ariadna Tibau

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Molecular Diagnosis & Therapy|March 2, 2017
Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer DrugsAriadna Tibau, Laura Díez-González, Beatriz Navarro, et al.
Plos One|May 6, 2016
Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-RegressionArnoud J Templeton, Laura Diez Gonzalez, Francisco E Vera-Badillo, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 24, 2021
Associations With Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Marketing Approval and in the Postmarketing PeriodAida Bujosa, Consolación Moltó, Thomas J Hwang, et al.
BMC Cancer|August 12, 2023
Treatment with anticancer drugs for advanced pancreatic cancer: a systematic reviewJosefina Salazar, Javier Bracchiglione, Olga Savall-Esteve, et al.
Journal of the National Cancer Institute|December 16, 2017
Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug AdministrationAriadna Tibau, Consolación Molto, Alberto Ocana, et al.
Biomedicines|December 23, 2023
Secreted Protein Acidic and Rich in Cysteine (<i>SPARC)</i> Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer PatientsCristina Arqueros, Juliana Salazar, Alberto Gallardo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugsAriadna Tibau, Philippe L Bedard, Amirrtha Srikanthan, et al.
International Journal of Molecular Sciences|March 13, 2024
Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant TherapyCristina Arqueros, Alberto Gallardo, Silvia Vidal, et al.
Neoplasia (New York, N.Y.)|November 8, 2014
Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancerAriadna Tibau, Laura López-Vilaró, Maitane Pérez-Olabarria, et al.
Therapeutic Advances in Medical Oncology|February 6, 2023
Quality of life with palbociclib plus fulvestrant <i>versus</i> placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trialAriadna Tibau, M Teresa Martínez, Manuel Ramos, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Molecular Diagnosis & Therapy|March 2, 2017
Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer DrugsAriadna Tibau, Laura Díez-González, Beatriz Navarro, et al.
Plos One|May 6, 2016
Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-RegressionArnoud J Templeton, Laura Diez Gonzalez, Francisco E Vera-Badillo, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 24, 2021
Associations With Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Marketing Approval and in the Postmarketing PeriodAida Bujosa, Consolación Moltó, Thomas J Hwang, et al.
BMC Cancer|August 12, 2023
Treatment with anticancer drugs for advanced pancreatic cancer: a systematic reviewJosefina Salazar, Javier Bracchiglione, Olga Savall-Esteve, et al.
Journal of the National Cancer Institute|December 16, 2017
Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug AdministrationAriadna Tibau, Consolación Molto, Alberto Ocana, et al.
Biomedicines|December 23, 2023
Secreted Protein Acidic and Rich in Cysteine (<i>SPARC)</i> Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer PatientsCristina Arqueros, Juliana Salazar, Alberto Gallardo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugsAriadna Tibau, Philippe L Bedard, Amirrtha Srikanthan, et al.
International Journal of Molecular Sciences|March 13, 2024
Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant TherapyCristina Arqueros, Alberto Gallardo, Silvia Vidal, et al.
Neoplasia (New York, N.Y.)|November 8, 2014
Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancerAriadna Tibau, Laura López-Vilaró, Maitane Pérez-Olabarria, et al.
Therapeutic Advances in Medical Oncology|February 6, 2023
Quality of life with palbociclib plus fulvestrant <i>versus</i> placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trialAriadna Tibau, M Teresa Martínez, Manuel Ramos, et al.
Pageof 5